UK GSK and German CureVac Announce Joint Plan to Develop 'Next-Generation Vaccine' Targeting COVID Variants
[Asia Economy Reporter Ki-min Lee] British pharmaceutical group GlaxoSmithKline (GSK) and German CureVac announced a joint plan to develop a vaccine capable of responding to various COVID-19 variants, AFP reported on the 3rd (local time).
In a joint statement, GSK and CureVac said, "This development program will start immediately with the goal of releasing a vaccine in 2022," but also mentioned that the specific vaccine launch timing may be somewhat flexible depending on regulatory approval.
They also stated that GSK will support the production of up to 100 million doses of CureVac's first-generation COVID vaccine candidate this year.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Over 7,000 Residents Evacuate Urgently" Magnitude 5.2 Earthquake Leaves 2 Dead, 6 Injured... What Happened in China?
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Major media outlets reported that GSK and CureVac have reached an agreement to develop a next-generation vaccine that can target multiple variants with a single product.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
